You are here

UPDATE

Aug 12, 2022, 02.15 PM

Lupin receives approval from US FDA for Meclizine Hydrochloride tablets USP

Meclizine Hydrochloride Tablets  had estimated annual sales of US$ 29 mn in the US (IQVIA MAT June 2022).

The product will be manufactured at Lupin’s facility in Goa, India.

Global pharma major Lupin Limited announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Meclizine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg, to market a generic equivalent of Antivert Tablets, 12.5 mg, 25 mg, and 50 mg, of Casper Pharma LLC. 

The product will be manufactured at Lupin’s facility in Goa, India.
 
Meclizine Hydrochloride Tablets  had estimated annual sales of US$ 29 mn in the US (IQVIA MAT June 2022).

Share Article